Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) in Patients With Selected Advanced Solid Tumors

Principal Investigator: Puzanov, Igor

Expanded Access Program for belantamab mafodotin in Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody

Principal Investigator: Hillengass, Jens

(S1900C) A Phase II Study of Talazoparib Plus Avelumab In Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (Lung-MAP Sub-Study)

Principal Investigator: Chen, Hongbin

A Phase 1b Trial of Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination with Azacitidine in Patients with Hematological Malignancies

Principal Investigator: Wang, Eunice S

(APEC1621D) NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)-PHASE 2 SUBPROTOCOL OF LY3023414 IN PATIENTS WITH SOLID TUMORS

Principal Investigator: Twist, Clare J

(ACNS1833) A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic…

Principal Investigator: Barth, Matthew J

A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naïve Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1 (ENGINE Study)

Principal Investigator: Hernandez-Ilizaliturri, Francisco J

A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab in Patients with Recurrent Ovarian Cancer

Principal Investigator: Odunsi, Adekunle O

Randomized phase II study of pembrolizumab q 12 weeks versus q 3 weeks in NSCLC with clinical benefit to pembrolizumab monotherapy: Multicenter International Study

Principal Investigator: Dy, Grace K

An Open label, Phase I/II study to evaluate the safety and efficacy of Tenalisib (RP6530), a novel PI3K Delta/Gamma dual inhibitor given in combination with a histone deacetylase (HDAC) inhibitor, Romidepsin in adult patients with relapsed/refractory T…

Principal Investigator: Sundaram, Suchitra

S1608) Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

Principal Investigator: Sundaram, Suchitra

A PHASE 1, MULTICENTER, OPEN-LABEL, DOSE FINDING STUDY OF CC-99712, A BCMA ANTIBODYDRUG CONJUGATE, IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA

Principal Investigator: Hillengass, Jens

Phase 2A Study Evaluating a Chemokine-Modulatory Regimen in Patients with Colorectal Cancer Metastatic to the Liver

Principal Investigator: Mukherjee, Sarbajit

A Phase Ib/II Study of Propranolol with Fixed-dose Pembrolizumab in Patients with Unresectable Stage III and Stage IV Melanoma

Principal Investigator: Gandhi, Shipra

Aromatherapy: An Integrative Option for Symptom Management in Cancer Care

Principal Investigator: Rokitka, Denise A

(ACNS1831) A Phase 3 Randomized Study of Selumetinib (IND # 77782) Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)

Principal Investigator: Barth, Matthew J

Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomization Trial

Principal Investigator: Levine, Ellis G

TISSUE AND DATA ACQUISITION ACTIVITY FOR THE STUDY OF GYNECOLOGIC DISEASE

Principal Investigator: Odunsi, Adekunle O

Impact of Menthol Delivery Methods on Smoker Sensory Perceptions

Principal Investigator: O'Connor, Richard J

A PHASE II TRIAL OF HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION UTILIZING MOBILIZED PERIPHERAL BLOOD STEM CELLS.

Principal Investigator: Balderman, Sophia R

AHOD1721, Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin(N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 +classic Hodgkin lymphoma (cHL) after failure of first-line…

Principal Investigator: Kelly, Kara M

A Multicenter Phase 2, Adaptive, Open-Label Trial of Intratumoral Tavokinogene Telseplasmid (tavo, pIL-12) plus Electroporation in Combination with Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressing on either Pembrolizumab or…

Principal Investigator: Puzanov, Igor

ADVL1622 Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors

Principal Investigator: Twist, Clare J

RCT of Online Mindfulness-Based Stress Reduction for Metastatic Breast Cancer Patients

Principal Investigator: Hydeman, Jennifer A

DFCI ALL Consortium 16-001: Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

Principal Investigator: Kelly, Kara M